This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Amgen, Inc.

Drug Names(s): panitumumab, ABX-EGF

Description: Vectibix is a XenoMouse-generated fully human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) with high affinity. Other drugs that impact this target are ImClone’s Erbitux (also a monoclonal antibody) and the small molecules Iressa from AstraZeneca and Tarceva from OSI, Roche, and Genentech. Iressa was the first approved EGFR inhibitor.

Deal Structure: Revenue splits are BioMedTracker estimates.

Immunex (Amgen) and Abgenix
In July 2000, Abgenix entered into a joint development and commercialization agreement with Immunex. Immunex was acquired by Amgen in 2002.

Amgen/Immunex paid Abgenix a license fee and will pay certain milestone fees. Amgen/Immunex and Abgenix will share responsibilities for phase II trials while Immunex will be responsible for phase III trials. Both Amgen/Immunex and Abgenix will have co-markeitng rights. Amgen/Immunex have been successful at designing and conducting phase III clinical trials. This co-development agreement decreases the risk that ABX-EGF's approval will be denied or delayed due to poorly designed or executed clinical trials.

Amgen completed its acquisition of Abgenix in April, 2006. Amgen acquired Abgenix for a total cash consideration of approximately $2.2 billion plus assumed debt. Amgen paid stockholders of Abgenix $22.50 in cash per share of common...See full deal structure in Biomedtracker

Partners: Takeda Pharmaceutical Company Ltd Beta Pharma Inc.

Vectibix News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug